A Multicenter, Randomized, Controlled Phase II Clinical Study of Comparison of Docetaxel for Injection (Albumin-bound) and Taxotere in Second-line or Above Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 26 Jun 2025
At a glance
- Drugs Docetaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 04 Jun 2024 Results( As of December 31, 2023, n=125 patients) focusing on efficacy and safety of HB1801 in patients with gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 06 Feb 2023 New trial record